Researchers have compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.
Don’t sack the director because your cancer center’s score and ranking by U.S. News & World Report have slipped.
Two years ago, as next-generation sequencing and checkpoint inhibitors became the standard of care in many cancers, Joan Massagué started hearing questions from philanthropists about the “next big thing” in cancer research.
The past two decades have been a golden age of discovery in genetics and cancer research. Using fast, affordable DNA sequencing, scientists have identified scores of gene mutations associated with cancer and developed highly effective drugs to target them.
Selwyn M. Vickers was named president and chief executive officer of Memorial Sloan Kettering Cancer Center.
The plenary session at the ASCO 2022 annual meeting saw that rarest of things at a scientific conference: a standing ovation.
All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery.
Last week, I became obsessed with reports that Vladimir Putin is a believer in an unproven remedy that involves bathing in blood drained from the horns of Siberian red deer.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Memorial Sloan Kettering Cancer Center showed that a small group of chronic lymphocytic leukemia patients experienced treatment-resistant mutations in a clinical trial for Loxo-305 (pirtobrutinib).
Ross Levine was named deputy physician-in-chief of translational research at Memorial Hospital, the main Manhattan hospital for Memorial Sloan Kettering Cancer Center.
